Aroa Biosurgery Gelecekteki Büyüme
Future kriter kontrolleri 4/6
Aroa Biosurgery kazanç ve gelirin sırasıyla yıllık 86.8% ve 13.2% oranında artacağı tahmin edilmektedir. EPS'nin yıllık 86.4% oranında büyümesi beklenmektedir. Özkaynak kârlılığının 3 yıl içinde 9.7% olacağı tahmin edilmektedir.
Anahtar bilgiler
86.8%
Kazanç büyüme oranı
86.41%
EPS büyüme oranı
| Biotechs kazanç büyümesi | 39.4% |
| Gelir büyüme oranı | 13.2% |
| Gelecekteki özkaynak getirisi | 9.65% |
| Analist kapsamı | Low |
| Son güncelleme | 05 May 2026 |
Gelecekteki son büyüme güncellemeleri
Aroa Biosurgery Limited (ASX:ARX) Just Reported Interim Earnings: Have Analysts Changed Their Mind On The Stock?
Aroa Biosurgery Limited ( ASX:ARX ) last week reported its latest half-yearly results, which makes it a good time for...The Aroa Biosurgery Limited (ASX:ARX) Interim Results Are Out And Analysts Have Published New Forecasts
It's been a good week for Aroa Biosurgery Limited ( ASX:ARX ) shareholders, because the company has just released its...Recent updates
ARX: Positive Wound Trial Results Will Support Stronger Future Profitability
Analysts have lifted their price target for Aroa Biosurgery from A$0.83 to A$1.07, citing updated assumptions that include a higher discount rate, a slightly adjusted revenue growth outlook, a stronger forecast profit margin, and a lower future P/E multiple. What's in the News Aroa Biosurgery reported completion of its randomised controlled trial of Symphony, a skin substitute designed for hard to heal wounds such as diabetic foot ulcers and venous leg ulcers, with a preliminary read out indicating the primary endpoint was achieved (Key Developments).
Reimbursement Shifts And Partner Dependence Will Reshape Tissue Regeneration Prospects Over Time
Catalysts About Aroa Biosurgery Aroa Biosurgery develops and supplies biologically derived soft tissue regeneration products used in wound care, reconstruction and surgical procedures. What are the underlying business or industry changes driving this perspective?
Outpatient Expansion And Surgical Partnerships Will Transform Long Term Prospects For This Biologics Supplier
Catalysts About Aroa Biosurgery Aroa Biosurgery develops and supplies biologically derived soft tissue regeneration products used in wound care, trauma, burns and reconstructive surgery. What are the underlying business or industry changes driving this perspective?Aroa Biosurgery Limited (ASX:ARX) Just Reported Interim Earnings: Have Analysts Changed Their Mind On The Stock?
Aroa Biosurgery Limited ( ASX:ARX ) last week reported its latest half-yearly results, which makes it a good time for...
Lebanon, Vietnam, And Saudi Arabia Approvals Will Secure Market Presence
Expansion into international markets and positive clinical outcomes suggest potential revenue growth as new regions adopt Aroa's cost-effective products.Why Investors Shouldn't Be Surprised By Aroa Biosurgery Limited's (ASX:ARX) 26% Share Price Plunge
Unfortunately for some shareholders, the Aroa Biosurgery Limited ( ASX:ARX ) share price has dived 26% in the last...Aroa Biosurgery (ASX:ARX) Is In A Strong Position To Grow Its Business
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com...Why Investors Shouldn't Be Surprised By Aroa Biosurgery Limited's (ASX:ARX) 26% Share Price Plunge
Aroa Biosurgery Limited ( ASX:ARX ) shareholders won't be pleased to see that the share price has had a very rough...Aroa Biosurgery Limited (ASX:ARX) Held Back By Insufficient Growth Even After Shares Climb 26%
Aroa Biosurgery Limited ( ASX:ARX ) shares have continued their recent momentum with a 26% gain in the last month...The Aroa Biosurgery Limited (ASX:ARX) Interim Results Are Out And Analysts Have Published New Forecasts
It's been a good week for Aroa Biosurgery Limited ( ASX:ARX ) shareholders, because the company has just released its...We're Not Worried About Aroa Biosurgery's (ASX:ARX) Cash Burn
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...Take Care Before Jumping Onto Aroa Biosurgery Limited (ASX:ARX) Even Though It's 29% Cheaper
Aroa Biosurgery Limited ( ASX:ARX ) shareholders won't be pleased to see that the share price has had a very rough...Investors Aren't Entirely Convinced By Aroa Biosurgery Limited's (ASX:ARX) Revenues
With a price-to-sales (or "P/S") ratio of 3.3x Aroa Biosurgery Limited ( ASX:ARX ) may be sending very bullish signals...Here's Why We're Not At All Concerned With Aroa Biosurgery's (ASX:ARX) Cash Burn Situation
Just because a business does not make any money, does not mean that the stock will go down. For example, although...Why Investors Shouldn't Be Surprised By Aroa Biosurgery Limited's (ASX:ARX) 25% Share Price Plunge
Aroa Biosurgery Limited ( ASX:ARX ) shareholders that were waiting for something to happen have been dealt a blow with...Aroa Biosurgery Limited's (ASX:ARX) Revenues Are Not Doing Enough For Some Investors
With a price-to-sales (or "P/S") ratio of 4.3x Aroa Biosurgery Limited ( ASX:ARX ) may be sending very bullish signals...Industry Analysts Just Made A Captivating Upgrade To Their Aroa Biosurgery Limited (ASX:ARX) Revenue Forecasts
Shareholders in Aroa Biosurgery Limited ( ASX:ARX ) may be thrilled to learn that the analysts have just delivered a...Aroa Biosurgery Limited's (ASX:ARX) Intrinsic Value Is Potentially 50% Above Its Share Price
Does the October share price for Aroa Biosurgery Limited ( ASX:ARX ) reflect what it's really worth? Today, we will...We Think Aroa Biosurgery (ASX:ARX) Can Easily Afford To Drive Business Growth
Just because a business does not make any money, does not mean that the stock will go down. For example, although...Here's What Analysts Are Forecasting For Aroa Biosurgery Limited (ASX:ARX) After Its Annual Results
Investors in Aroa Biosurgery Limited ( ASX:ARX ) had a good week, as its shares rose 6.2% to close at AU$1.20 following...An Intrinsic Calculation For Aroa Biosurgery Limited (ASX:ARX) Suggests It's 27% Undervalued
Today we'll do a simple run through of a valuation method used to estimate the attractiveness of Aroa Biosurgery...Do Institutions Own Aroa Biosurgery Limited (ASX:ARX) Shares?
A look at the shareholders of Aroa Biosurgery Limited ( ASX:ARX ) can tell us which group is most powerful...Don't Ignore The Fact That This Insider Just Sold Some Shares In Aroa Biosurgery Limited (ASX:ARX)
Anyone interested in Aroa Biosurgery Limited ( ASX:ARX ) should probably be aware that the Independent Non-Executive...Kazanç ve Gelir Büyüme Tahminleri
| Tarih | Gelir | Kazançlar | Serbest Nakit Akışı | Faaliyetlerden Nakit | Avg. Analist Sayısı |
|---|---|---|---|---|---|
| 3/31/2029 | 153 | N/A | N/A | N/A | 1 |
| 3/31/2028 | 137 | 14 | 16 | 18 | 3 |
| 3/31/2027 | 119 | 8 | 10 | 13 | 3 |
| 3/31/2026 | 104 | 4 | 10 | 11 | 3 |
| 9/30/2025 | 90 | -2 | 3 | 6 | N/A |
| 6/30/2025 | 88 | -3 | -2 | 2 | N/A |
| 3/31/2025 | 85 | -4 | -6 | -3 | N/A |
| 12/31/2024 | 81 | -6 | -9 | -4 | N/A |
| 9/30/2024 | 76 | -8 | -11 | -5 | N/A |
| 6/30/2024 | 73 | -9 | -13 | -6 | N/A |
| 3/31/2024 | 69 | -11 | -14 | -7 | N/A |
| 12/31/2023 | 67 | -9 | -15 | -7 | N/A |
| 9/30/2023 | 66 | -8 | -15 | -6 | N/A |
| 6/30/2023 | 65 | -4 | -13 | -5 | N/A |
| 3/31/2023 | 63 | 0 | -11 | -4 | N/A |
| 12/31/2022 | 57 | -1 | -13 | -7 | N/A |
| 9/30/2022 | 51 | -2 | -15 | -10 | N/A |
| 6/30/2022 | 45 | -5 | -16 | -11 | N/A |
| 3/31/2022 | 40 | -8 | -16 | -12 | N/A |
| 12/31/2021 | 35 | -10 | -14 | -10 | N/A |
| 9/30/2021 | 31 | -11 | -11 | -8 | N/A |
| 6/30/2021 | 27 | -15 | -9 | -6 | N/A |
| 3/31/2021 | 22 | -19 | -7 | -5 | N/A |
| 12/31/2020 | 22 | -19 | -6 | -5 | N/A |
| 9/30/2020 | 21 | -19 | -6 | -4 | N/A |
| 6/30/2020 | 23 | -12 | -3 | -1 | N/A |
| 3/31/2020 | 25 | -6 | 0 | 2 | N/A |
| 3/31/2019 | 24 | 1 | N/A | 0 | N/A |
| 3/31/2018 | 11 | -1 | N/A | -3 | N/A |
Analist Gelecek Büyüme Tahminleri
Kazançlar ve Tasarruf Oranları: ARX önümüzdeki 3 yıl içerisinde kârlı hale gelmesi öngörülüyor; bu da tasarruf oranından ( 3.6% ) daha hızlı bir büyüme olarak değerlendiriliyor.
Kazançlar ve Piyasa: ARX önümüzdeki 3 yıl içerisinde karlı hale gelmesi öngörülüyor ki bu da ortalama piyasa büyümesinin üzerinde kabul ediliyor.
Yüksek Büyüme Kazançları: ARX önümüzdeki 3 yıl içinde karlı hale gelmesi bekleniyor.
Gelir ve Pazar: ARX şirketinin gelirinin (yıllık 13.2% ) Australian pazarından (yıllık 6.1% ) daha hızlı büyümesi öngörülüyor.
Yüksek Büyüme Geliri: ARX şirketinin gelirinin (yıllık 13.2% ) yıllık 20% oranından daha yavaş büyümesi öngörülüyor.
Hisse Başına Kazanç Büyüme Tahminleri
Gelecekteki Özkaynak Getirisi
Gelecekteki ROE: ARX 'nin Özsermaye Getirisi'nin 3 yıl içinde düşük olması tahmin ediliyor ( 9.7 %).
Büyüyen şirketleri keşfedin
Şirket Analizi ve Finansal Veri Durumu
| Veri | Son Güncelleme (UTC saati) |
|---|---|
| Şirket Analizi | 2026/05/22 14:40 |
| Gün Sonu Hisse Fiyatı | 2026/05/22 00:00 |
| Kazançlar | 2025/09/30 |
| Yıllık Kazançlar | 2025/03/31 |
Veri Kaynakları
Şirket analizimizde kullanılan veriler S&P Global Market Intelligence LLC'den alınmıştır. Bu raporu oluşturmak için analiz modelimizde aşağıdaki veriler kullanılmıştır. Veriler normalize edilmiştir, bu da kaynağın mevcut olmasından kaynaklanan bir gecikmeye neden olabilir.
| Paket | Veri | Zaman Çerçevesi | Örnek ABD Kaynağı * |
|---|---|---|---|
| Şirket Finansalları | 10 yıl |
| |
| Analist Konsensüs Tahminleri | +3 yıl |
|
|
| Piyasa Fiyatları | 30 yıl |
| |
| Sahiplik | 10 yıl |
| |
| Yönetim | 10 yıl |
| |
| Önemli Gelişmeler | 10 yıl |
|
* ABD menkul kıymetleri için örnek, ABD dışı için eşdeğer düzenleyici formlar ve kaynaklar kullanılmıştır.
Belirtilmediği sürece tüm finansal veriler yıllık bir döneme dayanmaktadır ancak üç ayda bir güncellenmektedir. Bu, İzleyen On İki Ay (TTM) veya Son On İki Ay (LTM) Verileri olarak bilinir. Daha fazla bilgi edinin.
Analiz Modeli ve Kar Tanesi
Bu raporu oluşturmak için kullanılan analiz modelinin ayrıntılarına GitHub sayfamızdan ulaşabilirsiniz, ayrıca raporlarımızı nasıl kullanacağınızı anlatan kılavuzlarımız ve Youtube'da eğitim videolarımız da bulunmaktadır.
Simply Wall St analiz modelini tasarlayan ve oluşturan dünya standartlarındaki ekip hakkında bilgi edinin.
Endüstri ve Sektör Metrikleri
Sektör ve bölüm metriklerimiz Simply Wall St tarafından her 6 saatte bir hesaplanmaktadır, sürecimizin ayrıntıları Github'da mevcuttur.
Analist Kaynakları
Aroa Biosurgery Limited 5 Bu analistlerden 3, raporumuzun girdisi olarak kullanılan gelir veya kazanç tahminlerini sunmuştur. Analistlerin gönderimleri gün boyunca güncellenmektedir.
| Analist | Kurum |
|---|---|
| John Hester | Bell Potter |
| Elyse Shapiro | Canaccord Genuity |
| Shane Storey | Canaccord Genuity |